Trial Search Results
Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy
This randomized phase 3 trial studies how well modified Dakin's solution works in reducing radiation-induced dermatitis, a common skin reaction to radiation therapy, in patients with head and neck cancer undergoing radiation therapy. Modified Dakin's solution may reduce inflammation in the body, which may prevent or reduce dermatitis after radiation therapy.
Radiation therapy in this study is regulatory medical care based on the patient's needs and the radiation oncologist's judgment. It is not possible nor necessary to explicitly define the dose or duration of treatment.
Stanford is currently not accepting patients for this trial.
Collaborator: National Cancer Institute (NCI)
- Drug: Dakin's solution
- Other: Placebo
- Head and neck cancer who plan to undergo radiation therapy to the head and neck region
- At least 18 years of age
- Able to understand and the willingness to sign a written informed consent document.
- Prior radiation therapy to the head and neck region or prior chemotherapy for head and
neck cancer (induction chemotherapy NOT excluded)
- The physician-approved radiation treatment plan indicates a maximum prescription dose
of less than 45 Gy
- Scleroderma or discoid lupus
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study